Blueprint Medicines (NASDAQ:BPMC) Given “Outperform” Rating at Wedbush
Wedbush reaffirmed their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report report published on Thursday morning,RTT News reports. The firm currently has a $128.00 price objective on the biotechnology company’s stock, up from their prior price objective of $124.00. A number of other research firms have also weighed […]
Wedbush reaffirmed their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report report published on Thursday morning,RTT News reports. The firm currently has a $128.00 price objective on the biotechnology company’s stock, up from their prior price objective of $124.00. A number of other research firms have also weighed […]
